


AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims

1-14. **(Canceled)**

15. **(Currently amended)** A therapeutic method for a cancer, comprising the steps of:
~~extracting cancer cells from a patient suffering from a cancer;~~
confirming that ~~the~~ cancer cells from a patient are expressing excessive c-Kit kinase or a mutant c-Kit kinase; and
administering to the patient a pharmacologically effective dose of a compound represented by the general formula (I); ~~or a salt thereof or a hydrate of the foregoing:~~



wherein R¹ represents methyl, 2-methoxyethyl or a group represented by the formula (II):




wherein R^{a3} represents methyl, cyclopropylmethyl or cyanomethyl; R^{a1} represents hydrogen, fluorine or hydroxyl; and R^{a2} represents 1-pyrrolydiny, 1-piperidiny, 4-morpholinyl, dimethylamino or diethylamino;

R² represents cyano or -CONHR^{a4} wherein R^{a4} represents hydrogen, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy or C₃₋₈ cycloalkoxy;


R^3 represents hydrogen, methyl, trifluoromethyl, chlorine or fluorine; and
 R^4 represents hydrogen, methyl, ethyl, n-propyl, cyclopropyl, 2-thiazolyl or 4-fluorophenyl,

wherein the cancer is acute myelogenous leukemia, mast cell leukemia, small cell lung cancer, gastrointestinal stromal tumors, testicular cancer, ovarian cancer, breast cancer, brain cancer, neuroblastoma or colorectal cancer.

16. **(Currently amended)** A therapeutic method for mastocytosis, allergy or asthma, comprising administering to a patient suffering from the disease, a pharmacologically effective dose of a compound represented by the general formula (I), or a salt thereof ~~or a hydrate of the foregoing~~:



wherein R^1 represents methyl, 2-methoxyethyl or a group represented by the formula (II):




wherein R^{a3} represents methyl, cyclopropylmethyl or cyanomethyl; R^{a1} represents hydrogen, fluorine or hydroxyl; and R^{a2} represents 1-pyrrolydiny, 1-piperidiny, 4-morpholinyl, dimethylamino or diethylamino;


R^2 represents cyano or $-\text{CONHR}^{a4}$ wherein R^{a4} represents hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy or C_{3-8} cycloalkoxy;

R^3 represents hydrogen, methyl, trifluoromethyl, chlorine or fluorine; and
 R^4 represents hydrogen, methyl, ethyl, n-propyl, cyclopropyl, 2-thiazolyl or 4-fluorophenyl.

17. **(Currently amended)** A method comprising applying to a cell expressing excessive c-Kit kinase or a mutant c-Kit kinase, a pharmacologically effective dose of a compound represented by the general formula (I); ~~or a salt thereof or a hydrate of the foregoing~~:



wherein R¹ represents methyl, 2-methoxyethyl or a group represented by the formula (II):



wherein R^{a3} represents methyl, cyclopropylmethyl or cyanomethyl; R^{a1} represents hydrogen, fluorine or hydroxyl; and R^{a2} represents 1-pyrrolydiny, 1-piperidiny, 4-morpholiny, dimethylamino or diethylamino;

R² represents cyano or -CONHR^{a4} wherein R^{a4} represents hydrogen, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy or C₃₋₈ cycloalkoxy;

R³ represents hydrogen, methyl, trifluoromethyl, chlorine or fluorine; and

R⁴ represents hydrogen, methyl, ethyl, n-propyl, cyclopropyl, 2-thiazolyl or 4-fluorophenyl.

18. **(Currently amended)** The method according to claim ~~12~~ 16, wherein the compound represented by the formula(I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

19. **(Original)** The method according to claim 15, wherein the compound represented by the formula(I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-

quinolinecarboxamide.

20. **(Original)** The method according to claim 17, wherein the compound represented by the formula(I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.